Study Links JAK Inhibitors to Higher Arthritis Risk
Retrospective analysis of psoriasis patients compares psoriatic arthritis incidence across three biologic and targeted drug classes.
Updated on Nov. 17, 2026 in Arthritis

Live Poll
Would you feel more confident in a psoriasis drug your doctor says lowers joint-disease risk?
A retrospective study found that adults with psoriasis who started JAK inhibitors had a higher hazard of developing psoriatic arthritis than those who started IL-23 inhibitors, but a lower hazard than those who started IL-17 inhibitors. The research used the TriNetX federated research network and a target trial emulation design.
Why it matters
Psoriatic arthritis affects a substantial share of people with psoriasis, and the choice of treatment may influence whether joint disease develops. The findings offer comparative evidence that could inform discussions between patients and clinicians about treatment selection.
Matched cohorts of 5,027 and 5,300 adults per comparison were followed for up to five years, with cumulative psoriatic arthritis incidence of 15.1% to 27.1% depending on drug class. Negative control outcomes showed no between-group differences, but misclassification from diagnostic coding and unmeasured predictors remain open questions.
The players
SUNY Downstate Health Sciences University
A public academic health sciences university in Brooklyn, New York, with schools of medicine, nursing, and public health.
VA New York Harbor Healthcare System
A Veterans Affairs health system serving veterans across New York City and surrounding areas, with medical centers in Brooklyn and Manhattan.
The details
Researchers compared adults with psoriasis and no prior psoriatic arthritis who started JAK inhibitors with those starting IL-23 or IL-17 inhibitors, using propensity score matching on demographics, comorbidities, psoriasis subtype, baseline joint pain, prior medications, and health care utilization. Negative control outcomes such as presbyopia and ingrown nails showed no differences between groups.
Timeline
Follow-up for psoriatic arthritis outcomes extended up to 5 years.
Health Landscape
The findings extend earlier TriNetX-based work on biologic treatment outcomes in psoriasis, applying target trial emulation to a question that randomized trials have not directly answered for JAK inhibitors. The comparison adds to a growing body of real-world evidence on how drug class may shape the risk of progressing from skin disease to joint involvement.
For people with psoriasis, the study suggests that the choice between a JAK inhibitor and an IL-23 or IL-17 inhibitor may affect the likelihood of developing joint symptoms. Patients weighing these options should discuss their individual risk factors and joint history with their clinicians.
The takeaway
Treatment choice for psoriasis may influence the later risk of psoriatic arthritis, so patients with psoriasis should ask their clinicians how each drug class compares for joint outcomes.
Further reading
For background on the joint condition at the center of this research, see Arthritis.
Live Poll
Would you feel more confident in a psoriasis drug your doctor says lowers joint-disease risk?






